Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Title:	heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
Authors:	Kuemmel, Sherko^{Aff1, Aff2}; Harper-Wynne, Catherine^Aff3; Park, Yeon Hee^Aff4; Franke, Fábio^Aff5; de Laurentiis, Michelino^Aff6; Schumacher-Wulf, Eva^Aff7; Eiger, Daniel^Aff8; Heeson, Sarah^Aff9; Cardona, Andrés^Aff8; Özyilkan, Özgür^Aff10; Morales-Vàsquez, Flavia^Aff11; Metcalfe, Ciara^Aff12; Hafner, Marc^Aff12; Restuccia, Eleonora^Aff8; O’Shaughnessy, Joyce^{Aff13, IDs12885024121799_cor15}
Source:	BMC Cancer. 24(1)
Database:	Springer Nature Journals